Citadel Advisors
MEDS

Citadel Advisors’s DataMeds AI MEDS Stock Holding History

Citadel Advisors’s Portfolio MEDS Stock Details MEDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-596
Closed -$129K – 15708
2025
Q1 		$129K Buy
+596
New +$101K ﹤0.01% 11105

Other funds holding MEDS

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VFIC
Valley Forge Investment Consultants Audubon, Pennsylvania $388M AUM 22.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM

Citadel Advisors's MEDS Position: Q2 2025 in Review

Citadel Advisors sold out of DataMeds AI (MEDS) in Q2 2025, closing a stake of 596 shares — an estimated $129K sold.

Citadel Advisors first reported a position in MEDS in Q1 2025 and held it in 1 quarter. The position peaked at $129K in Q1 2025. 6 funds tracked by Wall St. Rank hold MEDS as of Q2 2025.

  • Citadel Advisors reported no remaining DataMeds AI position as of Q2 2025 after selling out during the quarter.
  • Citadel Advisors sold 596 DataMeds AI shares in Q2 2025, an estimated $129K.
  • Citadel Advisors first reported a position in DataMeds AI in Q1 2025 and held it in 1 quarter.
  • Citadel Advisors's DataMeds AI position peaked at $129K in Q1 2025.
  • 6 funds tracked by Wall St. Rank held DataMeds AI as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.